213 related articles for article (PubMed ID: 3089187)
21. Medical treatment of primary hyperparathyroidism: effects on parathormone and vitamin D metabolites.
Foldes J; Halperin Y; Kidroni G; Menczel J
Isr J Med Sci; 1987 Nov; 23(11):1148-51. PubMed ID: 3125129
[TBL] [Abstract][Full Text] [Related]
22. [Effects of the combined calcitonin and sodium etidronate therapy in Paget's disease of bone].
Nuti R; Turchetti V; Righi G; Vattimo A
Minerva Med; 1982 Mar; 73(9):467-72. PubMed ID: 6801555
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study.
Flores JF; Singer FR; Rude RK
Miner Electrolyte Metab; 1991; 17(6):390-5. PubMed ID: 1823390
[TBL] [Abstract][Full Text] [Related]
24. Treatment of acute lymphoblastic leukemia-induced extreme hypercalcemia with pamidronate and calcitonin.
Mathur M; Sykes JA; Saxena VR; Rao SP; Goldman GM
Pediatr Crit Care Med; 2003 Apr; 4(2):252-5. PubMed ID: 12749663
[TBL] [Abstract][Full Text] [Related]
25. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.
Fatemi S; Singer FR; Rude RK
Calcif Tissue Int; 1992 Feb; 50(2):107-9. PubMed ID: 1571826
[TBL] [Abstract][Full Text] [Related]
26. Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry.
Meunier PJ; Chapuy MC; Delmas P; Charhon S; Edouard C; Arlot M
Am J Med; 1987 Feb; 82(2A):71-8. PubMed ID: 3103438
[TBL] [Abstract][Full Text] [Related]
27. Effects of clodronate on immobilization bone loss.
Minaire P; Depassio J; Berard E; Meunier PJ; Edouard C; Pilonchery G; Goedert G
Bone; 1987; 8 Suppl 1():S63-8. PubMed ID: 2961357
[TBL] [Abstract][Full Text] [Related]
28. Primary hyperparathyroidism masquerading as immobilization hypercalcemia: report of an illustrative case.
Monno S; Yokozawa T; Mizushima Y; Nakayama J; Ohgaku S; Kato H; Takasu N; Kobayashi M
Endocr J; 1993 Feb; 40(1):35-9. PubMed ID: 7951494
[TBL] [Abstract][Full Text] [Related]
29. [Medical treatment of malignant hypercalcemia].
Eto S; Nakano Y; Okada Y
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
[TBL] [Abstract][Full Text] [Related]
30. Hypercalcemic complication in patients with oral squamous cell carcinoma.
Iwase M; Takemi T; Manabe M; Nagumo M
Int J Oral Maxillofac Surg; 2003 Apr; 32(2):174-80. PubMed ID: 12729778
[TBL] [Abstract][Full Text] [Related]
31. Human synthetic calcitonin therapy for hypercalcemia of immobilization.
Kaul S; Sockalosky JJ
J Pediatr; 1995 May; 126(5 Pt 1):825-7. PubMed ID: 7752017
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
[TBL] [Abstract][Full Text] [Related]
33. Immobilization hypercalcemia in an adult patient with pancreatitis and sepsis: case report.
Latham BB; Osterman J; Lin T; Nankin HR
J S C Med Assoc; 1992 Dec; 88(12):570-2. PubMed ID: 1487889
[TBL] [Abstract][Full Text] [Related]
34. Acute treatment with calcitonin in primary hyperparathyroidism and severe hypercalcaemia of other origin.
Sjöberg HE; Hjern B
Acta Chir Scand; 1975; 141(2):90-5. PubMed ID: 1171565
[TBL] [Abstract][Full Text] [Related]
35. Effects of intravenous etidronate disodium on skeletal and calcium metabolism.
Kanis JA; Urwin GH; Gray RE; Beneton MN; McCloskey EV; Hamdy NA; Murray SA
Am J Med; 1987 Feb; 82(2A):55-70. PubMed ID: 3103437
[TBL] [Abstract][Full Text] [Related]
36. A retrospective evaluation of the medical treatment of malignancy-associated hypercalcemia.
Kimura S; Sato Y; Matsubara H; Adachi I; Yamaguchi K; Suzuki M; Suemasu K; Abe K
Jpn J Cancer Res; 1986 Jan; 77(1):85-91. PubMed ID: 2937761
[TBL] [Abstract][Full Text] [Related]
37. [Life threatening hypercalcemia in a young man with ALL].
Schneider T; Seydlitz F; Zimmermann U; Sontag B; Boesken WH
Dtsch Med Wochenschr; 2001 Jan; 126(1-2):7-11. PubMed ID: 11200666
[TBL] [Abstract][Full Text] [Related]
38. Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium.
Jacobs TP; Gordon AC; Silverberg SJ; Shane E; Reich L; Clemens TL; Gundberg CM
Am J Med; 1987 Feb; 82(2A):42-50. PubMed ID: 3030098
[TBL] [Abstract][Full Text] [Related]
39. Management of severe hypercalcemia.
Davis KD; Attie MF
Crit Care Clin; 1991 Jan; 7(1):175-90. PubMed ID: 2007213
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous fat necrosis with hypercalcemia.
Vijayakumar M; Prahlad N; Nammalwar BR; Shanmughasundharam R
Indian Pediatr; 2006 Apr; 43(4):360-3. PubMed ID: 16651678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
